Follow the data: Bivalirudin (and not heparin alone) during percutaneous coronary intervention provides the best clinical outcomes

JACC: Cardiovascular Interventions

Volumn 8, Issue 1, 2015, Pages 225-227

  Stone, Gregg W ^a   Mehran, Roxana ^b   Steg, Philippe Gabriel ^c,d  

^a Department of Medicine   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Bivalirudin; Coronary artery disease; Heparin; Percutaneous coronary intervention

Indexed keywords

HEPARIN; HIRULOG; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ANTICOAGULANT THERAPY; ARTICLE; HUMAN; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; TREATMENT OUTCOME; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLEEDING; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; MORTALITY; MYOCARDIAL INFARCTION; PATIENT SELECTION; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE;

ANTICOAGULANTS; BLOOD PLATELETS; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MYOCARDIAL INFARCTION; PATIENT SELECTION; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84921370722     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.10.004     Document Type: Review

References (21)

1. Stone GW, Ohman EM. Antithrombin alternatives in STEMI. Lancet 2011;378:643-5.
2. Karvouni E, Katritsis DG, Ioannidis JPA. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32.
3. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005;293:1759-65.
4. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. JAMA 2006;295:1531-8.
5. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-9.
6. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008;359:688-96.
7. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63.
8. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16.
9. Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-STelevation myocardial infarction. N Engl J Med 2011;365:1980-9.
10. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30.
11. Steg PG, van't Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013;369:2207-17.
12. Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377:2193-204.
13. Rassen JA, Mittleman MA, Glynn RJ, et al. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J 2010; 31:561-72.
14. Wise GR, Schwartz BP, Dittoe N, et al. Comparative effectiveness analysis of anticoagulant strategies in a large observational database of percutaneous coronary interventions. J Interv Cardiol 2012;25:278-88.
15. Marso SP, Amin AP, House JA, et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA 2010;303:2156-64.
16. Baklanov DV, Kim S, Marso SP, et al. Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: analysis from the national cardiovascular data registry. Circ Cardiovasc Interv 2013;6:347-53.
17. Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014;384:1849-58.
18. Bellomo R, Warrillow SJ, Reade MC. Why we should be wary of single-center trials. Crit Care Med 2009;37:3114-9.
19. Zeymer U, van't Hof A, Adgey J, et al. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. Eur Heart J 2014;35:2460-7.
20. Han Y, for the BRIGHT Investigators. Bivalirudin versus heparin plus tirofiban in patients with AMI undergoing PCI. Available at: http://www.tctmd.com/show.aspx?id=126013. Accessed September 22, 2014.
21. ClinicalTrials.gov. Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX). Available at: http://clinicaltrials.gov/ct2/show/NCT01433627. Accessed November 4, 2014.